Tislelizumab is an IgG4 variant monoclonal antibody against PD-1 indicated for the treatment of esophageal squamous cell carcinoma and various lung cancers. It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis.
- Mechanism
- Curator reviewed · 2 references
Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.
Tislelizumab is a humanized immunoglobulin G4 (IgG4) variant monoclonal antibody against PD-1, binding to the extracellular domain of human PD-1. It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signalling and enhancing the functional activity in T cells in in vitro cell-based assays.
- Primary indication
- Esophageal Squamous Cell Carcinoma (ESCC) Tislelizumab, in combination with platinum-containing chemotherapy, is indicated as a first-line treatment in adults with unresectable or metastatic ESCC whose tumors express PD-L1.Curator reviewed · 28 structured indications
- First approval
- Canada, 2025 · United States, 2024 · European Union, 2024
- Also known as
- tirelizumab · Tirilizumab · Tislelizumab-jsgr
- Code names
- BGB-A317 · VDT482
- Brand names
Resolves to
What you can answer from here — as of September 05, 2026
Which drugs share a target with Tislelizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account